Patrick Mahaffy is a seasoned leader in the field of oncology-focused biotechnology with an emphasis on drug development and commercialization in the US and Europe Having successfully led multiple firms in the industry, each of which was based in Boulder, Colorado, Mr Mahaffy is now based in South Florida
Career History
An experienced biotech executive, Mahaffy most recently served as CEO of Clovis Oncology, a company he co-founded in 2009. Under his leadership, Clovis developed and marketed a drug for ovarian and prostate cancer in the US and Europe and commenced early-stage clinical development of a targeted radionuclide therapy, an exciting new area of oncology drug development Unfortunately, the company ultimately wound down in late 2022 due to the
negative impact of COVID-19 on cancer diagnoses and FDA concerns about the broader class of drugs in the treatment of ovarian cancer
Before taking the helm at Clovis, Mahaffy was the CEO of Pharmion from 2000 to 2008, when it was acquired by Celgene (now Bristol Myers Squibb), and Nexstar Pharmaceuticals from 1992 to 1998 when it was acquired by Gilead Sciences. Both firms successfully developed and marketed novel oncology drugs in the US and Europe.
Notably, the marketed drugs developed and commercialized under his leadership at each of the three companies remain the standard of care (or a member of the class that is the standard of care) for the conditions they are approved to treat.
Mahaffy began his career at Warburg Pincus, where he served as an investment banker from 1986 to 1992
Academic Background
Patrick Mahaffy holds a Master's degree in International Affairs from Columbia University, which he completed in 1986, a year after obtaining his Bachelor's degree in International Affairs from Lewis and Clark College